院前氨甲环酸对中重度创伤性脑损伤患者6个月神经功能结局的影响
这项多中心双盲随机临床试验纳入1280例中重度创伤性脑损伤患者,比较院前2小时内启动氨甲环酸与安慰剂对6个月神经功能结局的影响。结果显示,氨甲环酸组6个月良好神经功能比例为65%,安慰剂组为62%,差异无统计学意义。
要点
- 院前2小时内氨甲环酸并未显著改善6个月神经功能结局。
- 28天死亡率、6个月残疾评分及颅内出血进展均无显著差异。
- 该研究不支持对中重度创伤性脑损伤患者常规院前使用氨甲环酸。
核心结论
- 在中重度创伤性脑损伤患者中,与安慰剂相比,院前2小时内给予氨甲环酸并未显著改善6个月神经功能结局。
研究设计与样本
- 多中心、双盲、随机临床试验,在美国和加拿大的20个创伤中心和39个紧急医疗服务机构开展。
- 纳入1280例15岁及以上、格拉斯哥昏迷评分≤12分且收缩压≥90 mm Hg的院前创伤性脑损伤患者。
- 治疗在伤后2小时内启动,分为推注维持组、仅推注组和安慰剂组。
临床怎么用
- 对于中重度创伤性脑损伤患者,院前2小时内使用氨甲环酸未显示显著神经功能获益,不应作为常规治疗推荐。
局限性
- 分析人群为966例,随机化后96例未接受研究药物、1例被排除。
- 仅819例(84.8%)有6个月主要结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Traumatic brain injury (TBI) is the leading cause of death and disability due to trauma. Early administration of tranexamic acid may benefit patients with TBI. OBJECTIVE: To determine whether tranexamic acid treatment initiated in the out-of-hospital setting within 2 hours of injury improves neurologic outcome in patients with moderate or severe TBI. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blinded, randomized clinical trial at 20 trauma centers and 39 emergency medical services agencies in the US and Canada from May 2015 to November 2017. Eligible participants (N = 1280) included out-of-hospital patients with TBI aged 15 years or older with Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher. INTERVENTIONS: Three interventions were evaluated, with treatment initiated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group; n = 345), and out-of-hospital placebo bolus and in-hospital placebo 8-hour infusion (placebo group; n = 309). MAIN OUTCOMES AND MEASURES: The primary outcome was favorable neurologic function at 6 months (Glasgow Outcome Scale-Extended score >4 [moderate disability or good recovery]) in the combined tranexamic acid group vs the placebo group. Asymmetric significance thresholds were set at 0.1 for benefit and 0.025 for harm. There were 18 secondary end points, of which 5 are reported in this article: 28-day mortality, 6-month Disability Rating Scale score (range, 0 [no disability] to 30 [death]), progression of intracranial hemorrhage, incidence of seizures, and incidence of thromboembolic events. RESULTS: Among 1063 participants, a study drug was not administered to 96 randomized participants and 1 participant was excluded, resulting in 966 participants in the analysis population (mean age, 42 years; 255 [74%] male participants; mean Glasgow Coma Scale score, 8). Of these participants, 819 (84.8%) were available for primary outcome analysis at 6-month follow-up. The primary outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence limit for benefit, -0.9%]; P = .16; [97.5% 1-sided confidence limit for harm, 10.2%]; P = .84). There was no statistically significant difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7.9% to 2.1%]; P = .26), 6-month Disability Rating Scale score (6.8 vs 7.6; difference, -0.9 [95% CI, -2.5 to 0.7]; P = .29), or progression of intracranial hemorrhage (16% vs 20%; difference, -5.4% [95% CI, -12.8% to 2.1%]; P = .16). CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury compared with placebo did not significantly improve 6-month neurologic outcome as measured by the Glasgow Outcome Scale-Extended. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01990768.
引用
- Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020. PMID: 32897344. doi:10.1001/jama.2020.8958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。